TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SF7UUY3
| Market Closed - Deutsche Boerse AG 03:39:10 2024-05-31 pm EDT | ||
| 22.6 EUR | +5.41% |
|
| Current month | +28.26% | ||
| 1 month | +28.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 22.6 | +5.41% |
| 24-05-30 | 21.44 | -0.79% |
| 24-05-29 | 21.61 | -1.59% |
| 24-05-28 | 21.96 | -4.27% |
| 24-05-27 | 22.94 | +0.53% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 03:39 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UUY |
| ISIN | DE000SF7UUY3 |
| Date issued | 2021-08-18 |
| Strike | 211.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.98 € |
|---|---|
| Lowest since issue | 0.37 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
